Research
2010
201-500 Employees
Institut de Recerca Contra la Leucèmia Josep Carreras (IJC)Leukaemia, along with other malignant blood disorders, is one of the biggest challenges in the study and treatment of cancer in humans. For some time it has been one of the curable forms of cancer, so it is not surprising that currently the two cancers from which a large percentage of patients recover are acute lymphoblastic leukaemia (ALL) in children and Hodgkin’s lymphoma. However, one in four children with leukaemia die, as well as half of adult patients.

That is why the José Carreras International Foundation, together with the government, is launching an unprecedented project: the first research centre in Spain focusing exclusively on leukaemia and other haematological diseases, and one of the few such centres in the world.

Commitment to patients is the raison d’être of the Josep Carreras Leukemia Research Institute and, as such, it is imperative to strengthen efforts already being made in scientific research focused on leukaemia and other malignant blood disorders.
Address
Carretera de Can Ruti, Badalona, Spain

Institutional Contact for Facilities/Platforms

CERCAGINYS Facilities

Participated Spin-Offs

Barcelona, Spain

2015

LEUKOS BIOTECH SL

Barcelona, Spain

2020

ONECHAIN IMMUNOTHERAPEUTICS SL

GINJOL Technologies

2023-12-015 + 2021-08-009 - ALL-BePrecise-2 - Precision medicine in infant t(4;11) pro-B-ALL: targeting the novel biomarker HDAC7

Acute lymphoblastic leukemia (ALL) derived from B cell progenitors (pro-B-ALL) is the most prevalent type of cancer among children that are annually diagnosed of leukemia in Western countries. Despite an 80% of pediatric B-ALL remission has been achieved, a specific subgroup of infant patients (<1 year old) that present a translocation between chromosomes 4 and 11, commonly relapse, converting acute leukemia into the main cause of pediatric cancer-associated death. Survival rate of infants diagnosed with t(4;11) pro-B-ALL does not even reach 35%. Due to their short age and vulnerability, these patients are normally excluded from clinical trials rendering them to no further opportunities than non-targeted chemotherapy or "off-label" use of available drugs. Therefore, there is an urgent need to improve current available therapies. Recently, Dr Maribel Parra's group has identified HDAC7 as a prognostic factor in infants with this aggressive leukemia. These patients display a general loss in HDAC7 expression. The lowest levels of HDAC7 are associated with a poor outcome of the patients. Additional results show that HDAC7 is also lost in adult patients with t(4;11) pro-B-ALL and diffuse large B cell lymphoma (DLBCL), both aggressive diseases with low survival. Therefore, the identification of those blood cancer patients with low HDAC7 levels is a promising approach to implement personalized medicine strategies aiming to specifically induce HDAC7 expression. In this sense, a novel combinatorial therapy is being developed comprising MI-538 and Chidamide with the capacity to trigger HDAC7 expression in t(4;11) pro-B-ALL cells.

CERCA GÍNJOL

Main Domain of Research

Research Domain

Trustees

Trustees

Universities

Associated Universities

Other Public trustees

Sustainable Development Goals (SDG)

Objectius de Desenvolupament Sostenible (ODS)

Sustainable Development Goals (SDG)

*
Sustainable Development Goals